| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01554969 | Rectal Cancer | Drug: capecitabine + ganetespib | Emory University|Synta Pharmaceuticals Corp. | Phase 1 | 2012-05-01 | 2016-02-19 |
| NCT01485835 | Multiple Myeloma | Drug: Ganetespib|Drug: Bortezomib|Drug: Dexamethasone | Emory University|Multiple Myeloma Research Consortium|Synta Pharmaceuticals Corp. | Phase 1 | 2012-01-01 | 2015-10-08 |
| NCT02008877 | Malignant Peripheral Nerve Sheath Tumors (MPNST)|Sarcoma | Drug: ganetespib|Drug: Sirolimus | Sarcoma Alliance for Research through Collaboration|Synta Pharmaceuticals Corp.|United States Department of Defense | Phase 1|Phase 2 | 2013-12-01 | 2016-10-12 |
| NCT01560416 | Breast Cancer | Drug: Fulvestrant|Drug: Ganetespib | Dana-Farber Cancer Institute | Phase 2 | 2012-05-01 | 2017-01-17 |
| NCT01562015 | Non Small Cell Lung Cancer | Drug: Ganetespib | Synta Pharmaceuticals Corp. | Phase 2 | 2012-04-01 | 2015-05-18 |
| NCT02261805 | Cancer|Small Cell Lung Cancer | Drug: Ganetespib and doxorubicin | Georgetown University|Synta Pharmaceuticals Corp. | Phase 1|Phase 2 | 2014-10-01 | 2016-12-30 |
| NCT01798485 | Non-Small-Cell Lung Adenocarcinoma|Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV|Non-small Cell Lung Cancer Metastatic | Drug: Docetaxel|Drug: Ganetespib | Synta Pharmaceuticals Corp. | Phase 3 | 2013-04-01 | 2016-05-26 |
| NCT01039519 | Gastrointestinal Stromal Tumor | Drug: Ganetespib | Synta Pharmaceuticals Corp. | Phase 2 | 2010-01-01 | 2016-02-11 |
| NCT01579994 | Advanced Lung Cancer | Drug: Ganetespib (STA-9090) and crizotinib | Memorial Sloan Kettering Cancer Center | Phase 1 | 2012-04-01 | 2017-03-13 |
| NCT00687934 | Solid Tumors | Drug: STA-9090 | Synta Pharmaceuticals Corp. | Phase 1 | 2007-10-01 | 2014-09-17 |
| NCT01962948 | Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer | Drug: paclitaxel|Drug: ganetespib|Other: laboratory biomarker analysis | Fox Chase Cancer Center|National Cancer Institute (NCI) | Phase 1|Phase 2 | 2013-10-01 | 2016-11-23 |
| NCT02389751 | Esophageal Cancer | Drug: Ganetespib|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Radiotherapy | M.D. Anderson Cancer Center|Synta Pharmaceuticals Corp. | Phase 1 | 2015-04-01 | 2017-03-13 |
| NCT02060253 | HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | Drug: ganetespib|Drug: paclitaxel|Biological: trastuzumab|Biological: pertuzumab | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Synta Pharmaceuticals Corp.|New York University Cancer Institute | Phase 1 | 2014-04-01 | 2016-07-11 |
| NCT01183364 | Solid Tumor Malignancies | Drug: STA-9090 (ganetespib) with Docetaxel | Synta Pharmaceuticals Corp. | Phase 1 | 2010-07-01 | 2014-09-18 |
| NCT00688116 | Solid Tumors | Drug: STA 9090 (ganetespib) | Synta Pharmaceuticals Corp. | Phase 1 | 2007-10-01 | 2014-09-17 |
| NCT01677455 | Breast Cancer|HER-2 Positive Breast Cancer|Triple Negative Breast Cancer|ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment | Drug: ganetespib | Synta Pharmaceuticals Corp. | Phase 2 | 2012-07-01 | 2015-11-04 |
| NCT01167114 | Esophagogastric Cancer | Drug: STA-9090 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Synta Pharmaceuticals Corp. | Phase 2 | 2010-08-01 | 2017-01-06 |
| NCT01665937 | Hepatocellular Carcinoma | Drug: STA-9090 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Synta Pharmaceuticals Corp. | Phase 1 | 2010-08-01 | 2014-03-19 |
| NCT01590160 | Lung Cancer - Malignant Pleural Mesothelioma | Drug: Ganetespib | University College, London|Cancer Research UK | Phase 1|Phase 2 | 2013-08-01 | 2016-10-26 |
| NCT01368003 | Adenocarcinoma of the Prostate | Drug: STA9090|Drug: STA9090 with Dutasteride | Toni Choueiri, MD|Dana-Farber Cancer Institute | Phase 2 | 2011-04-01 | 2015-08-29 |
| NCT02012192 | Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | Drug: Ganetespib|Drug: Paclitaxel | Medical University Innsbruck|European Commission | Phase 1|Phase 2 | 2014-06-01 | 2016-12-05 |
